Conditions, Process, and Considerations for Genetic Disease Carriers Undergoing IVF in Hong Kong

AI Summary

Main Content Begins

Can Genetic Disease Carriers Undergo IVF in Hong Kong?

Yes. Genetic disease carriers can absolutely undergo IVF treatment in Hong Kong and, with the help of Preimplantation Genetic Testing (PGT) technology, block the intergenerational transmission of specific genetic diseases at the source. The Hong Kong Council on Human Reproductive Technology strictly regulates related technologies under the "Human Reproductive Technology Ordinance" (Chapter 561), explicitly allowing genetic diagnosis of embryos when medically necessary.

Eligible individuals include: carriers of monogenic diseases (autosomal recessive, dominant, and X-linked), carriers of balanced chromosomal translocations/Robertsonian translocations, and individuals with a clear family history of genetic diseases who have not yet developed the condition themselves. The most common clinical indications include β-thalassemia, α-thalassemia, spinal muscular atrophy (SMA), hereditary deafness, hemophilia, cystic fibrosis, and Huntington's disease.

Why Do Genetic Disease Carriers Need PGT Technology?

Genetic disease carriers themselves usually do not develop the disease or have only mild symptoms, but their offspring face a clear genetic risk during natural pregnancy. Taking autosomal recessive genetic diseases as an example, if both partners are carriers of the same pathogenic gene, each pregnancy has a 25% chance of having an affected child, a 50% chance of the child being a carrier, and only a 25% chance of being completely normal. For autosomal dominant genetic diseases, offspring of a carrier have a 50% chance of developing the disease.

Traditional prenatal diagnosis (e.g., amniocentesis, chorionic villus sampling) can only confirm whether the fetus is affected in the second trimester. If diagnosed as affected, the couple faces the ethical dilemma and physical trauma of terminating the pregnancy. PGT technology advances genetic testing to before embryo transfer, selecting only embryos that do not carry the pathogenic gene for transfer, fundamentally avoiding pregnancies affected by genetic diseases.

Hong Kong's PGT technology system is aligned with European and American standards. Laboratories commonly use next-generation sequencing (NGS) platforms, combined with single nucleotide polymorphism (SNP) linkage analysis or whole genome amplification technology, enabling simultaneous detection of multiple loci and effectively distinguishing between normal embryos and carrier embryos.

Eligible and Ineligible Individuals

Genetic Disease Carriers Suitable for PGT

• Confirmed carriers of monogenic diseases: One or both partners are confirmed as carriers of a pathogenic gene through genetic testing, with clear pathogenicity and mature testing methods.
• Carriers of chromosomal structural abnormalities: Such as balanced translocations, Robertsonian translocations, inversions, etc., leading to recurrent miscarriage or increased risk of having children with chromosomal abnormalities.
• Family history of genetic disease with known gene locus: A proband in the family has completed genetic diagnosis, and the pathogenic locus is clear.
• Advanced maternal age combined with genetic risk: Female age ≥ 38 years and also a genetic disease carrier, may consider combined PGT-A and PGT-M screening.
• Previous birth of a child with a genetic disease: Desire to minimize the risk of recurrence before a subsequent pregnancy.

Ineligible or Requiring Cautious Evaluation

• Pathogenic gene not identified: Only a family history exists without a specific pathogenic locus, making it impossible to establish a testing system.
• Polygenic genetic diseases: Such as congenital heart disease, diabetes, schizophrenia, etc., caused by multiple genes and environmental factors; current PGT technology cannot effectively predict these.
• Mitochondrial diseases (some types): The mechanism of mitochondrial inheritance is complex, and PGT testing has limitations; case-by-case evaluation is needed.
• Severely diminished ovarian reserve: Too few eggs retrieved may result in no embryos available for testing; ovarian function assessment should be done in advance.
• Medical contraindications: Such as uncontrolled endocrine diseases, malignant tumors, severe uterine abnormalities, etc.; the primary issue must be addressed first.

Reproductive Medicine Perspective: How Doctors View IVF Treatment for Genetic Disease Carriers

From a clinical standpoint, IVF treatment for genetic disease carriers is not simply "infertility treatment" but rather a reproductive genetic intervention. When formulating a plan, doctors must consider two aspects simultaneously: first, the success factors of conventional IVF (female age, ovarian response, embryo quality, etc.), and second, the special requirements of genetic testing.

Reproductive medicine centers in Hong Kong typically adopt a multidisciplinary collaboration model, involving reproductive endocrinologists, genetic counselors, embryologists, and clinical geneticists in developing the plan. Doctors focus on the following key areas:

• Genetic counseling upfront: Complete a comprehensive genetic risk assessment before starting the cycle, including the inheritance pattern of the pathogenic gene, penetrance, and the sensitivity and specificity of the testing method.
• Necessity of pedigree verification: Approximately 30% of cases require samples from the proband or parents for linkage analysis; otherwise, it is impossible to distinguish between normal embryos and carrier embryos.
• Timing and safety of embryo biopsy: Hong Kong commonly uses blastocyst-stage trophectoderm biopsy (days 5–6), which has less impact on embryo developmental potential compared to cleavage-stage biopsy.
• Selection of testing platform: PGT-M combined with haplotype analysis is recommended for monogenic diseases, PGT-SR for chromosomal structural abnormalities, and PGT-A can be added for older women at risk of aneuploidy.

Actual Process of PGT IVF Treatment in Hong Kong

From the initial consultation to transfer, a complete PGT cycle typically includes the following steps:

From starting ovarian stimulation to obtaining results for transferable embryos, the minimum time is approximately 8–10 weeks. If pedigree verification is needed or the testing protocol is complex, the preparatory phase may extend to 2–3 months.

Timeline and Key Milestones

For genetic disease carriers, the focus of time planning is not on the stimulation itself but on establishing the genetic testing protocol. The following time points require special attention:

• Family sample collection: Peripheral blood or saliva samples from the proband (affected family member) must be available before starting the cycle. If the proband is outside Hong Kong, logistics and customs time must be considered.
• Testing probe preparation: Some laboratories need to design personalized probes for specific mutations, taking 1–2 weeks.
• Embryo testing window: The testing period after biopsy is typically 14–21 days; the laboratory will provide an estimated report date.
• Transfer window: After obtaining results, transfer must occur within the female's ovulatory window or hormone replacement cycle window; missing it means waiting for the next cycle.

Easily Overlooked Details

Based on clinical feedback, the following aspects are often underestimated or overlooked in the treatment of genetic disease carriers:

• Genetic counseling is not a one-time communication: Some couples think they can proceed directly to the cycle after counseling, but multiple sessions are needed to confirm the testing strategy, sign informed consent, and complete psychological assessment.
• Disposition of carrier embryos: For autosomal recessive diseases, carrier embryos are generally considered "transferable" because carriers themselves do not develop the disease. However, acceptance varies between centers and couples, requiring prior consensus.
• Genetic counseling follow-up for results: After receiving the embryo testing report, a genetic counselor must explain the results in detail, including limitations and residual risks, rather than just looking at "normal" or "abnormal" labels.
• Hong Kong legal restrictions on embryo manipulation: According to the "Human Reproductive Technology Ordinance," genetic testing of embryos must be conducted in licensed institutions and cannot be used for non-medical sex selection or gene editing. The number of embryos tested and biopsy methods must comply with regulations.
• Differences from mainland legal environment: Hong Kong's approval of PGT indications focuses more on clinical medical necessity than administrative access. Some genetic disease indications prohibited or restricted in mainland China (e.g., certain adult-onset dominant genetic diseases) can be approved on a case-by-case basis in Hong Kong.

Frequently Asked Questions

1. Can all genetic diseases be detected by PGT in Hong Kong?

No. PGT is currently mainly applicable to monogenic diseases and chromosomal structural abnormalities. Polygenic diseases, mitochondrial diseases (some types), and genetic diseases with unidentified pathogenic genes cannot be tested. Furthermore, even if the gene locus is known, if the testing technology cannot effectively distinguish between normal and carrier status (e.g., certain synonymous mutations or copy number variations), a testing protocol may not be established.

2. How accurate is PGT?

For specific monogenic mutations, the detection accuracy is over 98%–99%. However, the following situations may lead to result discrepancies: embryo DNA amplification failure (approximately 2–5%), allele dropout (ADO), and maternal contamination. Therefore, PGT results cannot replace prenatal diagnosis; amniocentesis or chorionic villus sampling is recommended for confirmation after all PGT pregnancies.

3. Is PGT necessary if there is no family history of genetic disease?

If there is no family history and you are not a known carrier, it is usually not necessary. However, if both partners are carriers of a recessive genetic disease (identified through expanded carrier screening), there is a 25% risk of having an affected child, making PGT medically necessary. Some reproductive centers in Hong Kong recommend that couples planning IVF complete expanded carrier screening before starting the cycle.

4. What are the main differences between PGT in Hong Kong and third-generation IVF in mainland China?

The core difference lies in the regulatory framework and the approval method for indications. Hong Kong adopts a "case-by-case approval system," allowing PGT as long as it is medically necessary and the laboratory is qualified. Mainland China implements an "access system," with stricter limits on the number and technical scope of PGT institutions. Additionally, Hong Kong allows the transfer of carrier embryos (with the couple's informed consent), while mainland China has stricter restrictions on this. In terms of testing technology platforms, both regions primarily use NGS, with no essential difference.

5. What is the approximate cost range for PGT in Hong Kong?

The total cost for a complete IVF+PGT cycle is approximately between HKD 120,000 and 250,000, depending on: the number of gene loci tested (single gene vs. multi-gene panel), whether pedigree linkage analysis is required, whether PGT-A screening is done simultaneously, and medication costs and laboratory fees. The initial consultation fee is approximately HKD 1,500–3,000, with genetic testing fees charged separately.

Summary Recommendations

For genetic disease carriers, achieving genetic prevention through PGT IVF technology in Hong Kong is a mature and legal pathway. The keys to success are: clear genetic diagnosis, thorough pre-treatment genetic counseling, reasonable cycle planning, and rational understanding of the technology's limitations. It is recommended to complete the following three things before starting treatment: confirm the pathogenic gene locus and complete pedigree verification; choose a reproductive center licensed by the Hong Kong Council on Human Reproductive Technology; and work with a genetic counselor and reproductive doctor to develop a comprehensive treatment plan that includes alternative options.

This content is based on Hong Kong's "Human Reproductive Technology Ordinance" and clinical reproductive medicine practices and does not constitute personal medical advice. Please consult a licensed physician for specific diagnosis and treatment plans.